All Outputs (18)

Yttrium-Enriched Phosphate Glass-Ceramic Microspheres for Bone Cancer Radiotherapy Treatment (2024)
Journal Article
Milborne, B., Arjuna, A., Islam, T., Arafat, A., Layfield, R., Thompson, A., & Ahmed, I. (in press). Yttrium-Enriched Phosphate Glass-Ceramic Microspheres for Bone Cancer Radiotherapy Treatment. Journal of the American Chemical Society,

This study presents the development and characterisation of high yttrium-content phosphate-based glass-ceramic microspheres for potential applications in bone cancer radiotherapy treatment. The microspheres produced via flame spheroidisa-tion, follow... Read More about Yttrium-Enriched Phosphate Glass-Ceramic Microspheres for Bone Cancer Radiotherapy Treatment.

Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML (2023)
Journal Article
James, J. R., Curd, J., Ashworth, J. C., Abuhantash, M., Grundy, M., Seedhouse, C. H., …Thompson, A. (2023). Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML. International Journal of Molecular Sciences, 24(4), Article 4235. https://doi.org/10.3390/ijms24044235

In vivo models of acute myeloid leukemia (AML) are low throughput, and standard liquid culture models fail to recapitulate the mechanical and biochemical properties of the extracellular matrix-rich protective bone marrow niche that contributes to dru... Read More about Hydrogel-Based Pre-Clinical Evaluation of Repurposed FDA-Approved Drugs for AML.

Developing Porous Ortho- and Pyrophosphate-Containing Glass Microspheres; Structural and Cytocompatibility Characterisation (2022)
Journal Article
Milborne, B., Murrell, L., Cardillo-Zallo, I., Titman, J., Briggs, L., Scotchford, C., …Ahmed, I. (2022). Developing Porous Ortho- and Pyrophosphate-Containing Glass Microspheres; Structural and Cytocompatibility Characterisation. Bioengineering, 9(11), Article 611. https://doi.org/10.3390/bioengineering9110611

Phosphate-based glasses (PBGs) are promising materials for bone repair and regeneration as they can be formulated to be compositionally similar to the inorganic components of bone. Alterations to the PBG formulation can be used to tailor their degrad... Read More about Developing Porous Ortho- and Pyrophosphate-Containing Glass Microspheres; Structural and Cytocompatibility Characterisation.

Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial (2020)
Journal Article
Langton Hewer, S. C., Smyth, A. R., Brown, M., Jones, A. P., Hickey, H., Kenna, D., …Williamson, P. R. (2020). Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respiratory Medicine, 8(10), 975-986. https://doi.org/10.1016/S2213-2600%2820%2930331-3

Background: Chronic pulmonary infection with Pseudomonas aeruginosa is one of the most important causes of mortality and morbidity in cystic fibrosis. If antibiotics are commenced promptly, infection can be eradicated. The aim of the trial was to com... Read More about Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.

The Use of Biomaterials in Internal Radiation Therapy (2020)
Journal Article
Milborne, B., Arafat, A., Layfield, R., Thompson, A., & Ahmed, I. (2020). The Use of Biomaterials in Internal Radiation Therapy. Recent Progress in Materials, 2(2), Article 34. https://doi.org/10.21926/rpm.2002012

Radiotherapy has become one of the most prominent and effective modalities for cancer treatment and care. Ionising radiation, delivered either from external or internal sources, can be targeted to cancerous cells causing damage to DNA that can induce... Read More about The Use of Biomaterials in Internal Radiation Therapy.

Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the AAVS1 locus as not an entirely safe harbour (2019)
Journal Article
Bhagwan, J. R., Collins, E., Mosqueira, D., Bakar, M., Johnson, B. B., Thompson, A., …Denning, C. (in press). Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the AAVS1 locus as not an entirely safe harbour. F1000Research, 8, Article 1911. https://doi.org/10.12688/f1000research.19894.1

Background: Diseases such as hypertrophic cardiomyopathy (HCM) can lead to severe outcomes including sudden death. The generation of human induced pluripotent stem cell (hiPSC) reporter lines can be useful for disease modelling and drug screening by... Read More about Variable expression and silencing of CRISPR-Cas9 targeted transgenes identifies the AAVS1 locus as not an entirely safe harbour.

The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells (2019)
Journal Article
Clarke, K., Young, C., Liberante, F., McMullin, M. F., Thompson, A., & Mills, K. (2019). The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells. Oncotarget, 10(37), 3462-3471. https://doi.org/10.18632/oncotarget.26877

© 2020 Ivyspring International Publisher. All rights reserved. Myelodysplastic syndromes (MDS) are a heterogeneous, clonal haematopoietic disorder, with ~1/3 of patients progressing to acute myeloid leukaemia (AML). Many elderly MDS patients do not t... Read More about The histone deacetylase inhibitor Romidepsin induces as a cascade of differential gene expression and altered histone H3K9 marks in myeloid leukaemia cells.

HOX genes in normal, engineered and malignant hematopoiesis (2018)
Journal Article
Collins, E. M., & Thompson, A. (2018). HOX genes in normal, engineered and malignant hematopoiesis. International Journal of Developmental Biology, 62(11-12), 847-856. https://doi.org/10.1387/ijdb.180206at

© 2018 UPV/EHU Press. Advanced technologies and models systems are improving our understanding of developmental processes. A primary example, hematopoiesis, classically represented by a hierarchical tree with a stem cell at the apex and more lineage... Read More about HOX genes in normal, engineered and malignant hematopoiesis.

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells (2017)
Journal Article
Alharbi, R. A., Pandha, H. S., Simpson, G. R., Pettengell, R., Poterlowicz, K., Thompson, A., …Morgan, R. (2017). Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells. Oncotarget, 8(52), https://doi.org/10.18632/oncotarget.20023

The HOX genes encode a family of transcription factors that have key roles in both development and malignancy. Disrupting the interaction between HOX proteins and their binding partner, PBX, has been shown to cause apoptotic cell death in a range of... Read More about Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy (2017)
Journal Article
Hay, J. F., Lappin, K., Liberante, F., Kettyle, L. M., Matchett, K. B., Thompson, A., & Mills, K. I. (2017). Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy. Oncotarget, 8(40), https://doi.org/10.18632/oncotarget.18910

Several histone deacetylase inhibitors including Vorinostat have received FDA approval for the treatment of haematological malignancies. However, data from these trials indicate that Vorinostat has limited efficacy as a monotherapy, prompting the nee... Read More about Integrated analysis of the molecular action of Vorinostat identifies epi-sensitised targets for combination therapy.

Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy (2017)
Journal Article
Young, C. S., Clarke, K. M., Kettyle, L. M., Thompson, A., & Mills, K. I. (2017). Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy. Oncotarget, 8(31), https://doi.org/10.18632/oncotarget.18009

Despite advancements in cancer therapeutics, acute myeloid leukemia patients over 60 years old have a 5-year survival rate of less than 8%. In an attempt to improve this, epigenetic modifying agents have been combined as therapies in clinical studies... Read More about Decitabine-Vorinostat combination treatment in acute myeloid leukemia activates pathways with potential for novel triple therapy.

Low-dose salinomycin induces anti-leukemic responses in AML and MLL (2016)
Journal Article
Roulston, G. D., Burt, C. L., Kettyle, L. M., Matchett, K. B., Keenan, H. L., Mulgrew, N. M., …Thompson, A. (2016). Low-dose salinomycin induces anti-leukemic responses in AML and MLL. Oncotarget, https://doi.org/10.18632/oncotarget.11866

Development of anti-cancer drugs towards clinical application is costly and inefficient. Large screens of drugs, efficacious for non-cancer disease, are currently being used to identify candidates for repurposing based on their anti-cancer properties... Read More about Low-dose salinomycin induces anti-leukemic responses in AML and MLL.

Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing (2016)
Journal Article
Dhami, S. P. S., Kappala, S. S., Thompson, A., & Szegezdi, E. (in press). Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing. Drug Discovery Today, 21(9), https://doi.org/10.1016/j.drudis.2016.04.019

Acute myeloid leukaemia (AML) is a hierarchically structured malignancy in which aberrant leukemic stem cells drive the production of leukaemic blast cell clones. AML cells strictly depend on the bone marrow microenvironment (BMM) in which they resid... Read More about Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing.

Hoxa cluster genes determine the proliferative activity of adult mouse hematopoietic stem and progenitor cells (2015)
Journal Article
Lebert-Ghali, C.-É., Fournier, M., Kettyle, L. M., Thompson, A., Sauvageau, G., & Bijl, J. J. (2016). Hoxa cluster genes determine the proliferative activity of adult mouse hematopoietic stem and progenitor cells. Blood, 127(1), 87-90. https://doi.org/10.1182/blood-2015-02-626390

Determination of defined roles for endogenous homeobox (Hox) genes in adult hematopoietic stem and progenitor cell (HSPC) activity has been hampered by a combination of embryonic defects and functional redundancy. Here we show that conditional homozy... Read More about Hoxa cluster genes determine the proliferative activity of adult mouse hematopoietic stem and progenitor cells.

POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer (2014)
Journal Article
Sharpe, D. J., Orr, K. S., Moran, M., White, S. J., McQuaid, S., Lappin, T. R., …James, J. A. (2014). POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer. Oncotarget, 5(18), https://doi.org/10.18632/oncotarget.2492

HOX genes are master regulators of organ morphogenesis and cell differentiation during embryonic development, and continue to be expressed throughout post-natal life. To test the hypothesis that HOX genes are dysregulated in head and neck squamous ce... Read More about POU2F1 activity regulates HOXD10 and HOXD11 promoting a proliferative and invasive phenotype in head and neck cancer.

Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia (2014)
Journal Article
Kettyle, L. M., Liberante, F. G., & Thompson, A. (2014). Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia. Methods in Molecular Biology, 1196, https://doi.org/10.1007/978-1-4939-1242-1_21

Drug discovery and development are often hampered by lack of target identification and clinical tractability. Repurposing of approved drugs to life-threatening diseases such as leukemia is emerging as a promising alternative approach. Connectivity ma... Read More about Rational drug repurposing using sscMap analysis in a HOX-TALE model of leukemia.

c-Met inhibition in aHOXA9/Meis1model of CN-AML (2013)
Journal Article
Mulgrew, N. M., Kettyle, L. M., Ramsey, J. M., Cull, S., Smyth, L. J., Mervyn, D. M., …Thompson, A. (2013). c-Met inhibition in aHOXA9/Meis1model of CN-AML. Developmental Dynamics, 243(1), https://doi.org/10.1002/dvdy.24070

Background: Hematopoiesis is a paradigm for developmental processes, hierarchically organized, with stem cells at its origin. Hematopoietic stem cells (HSCs) replenish progenitor and precursor cells of multiple lineages, which normally differentiate... Read More about c-Met inhibition in aHOXA9/Meis1model of CN-AML.

Hoxa9 collaborates with E2A-PBX1 in mouse B cell leukemia in association with Flt3 activation and decrease of B cell gene expression (2013)
Journal Article
Hassawi, M., Shestakova, E. A., Fournier, M., Lebert-Ghali, C.-É., Vaisson, G., Frison, H., …Bijl, J. J. (2014). Hoxa9 collaborates with E2A-PBX1 in mouse B cell leukemia in association with Flt3 activation and decrease of B cell gene expression. Developmental Dynamics, 243(1), 145-158. https://doi.org/10.1002/dvdy.24056

Background: The fusion protein E2A-PBX1 induces pediatric B cell leukemia in human. Previously, we reported oncogenic interactions between homeobox (Hox) genes and E2A-PBX1 in murine T cell leukemia. A proviral insertional mutagenesis screen with our... Read More about Hoxa9 collaborates with E2A-PBX1 in mouse B cell leukemia in association with Flt3 activation and decrease of B cell gene expression.